ESR1 and breast carcinoma: Epidemiologic data have shown that ER-positive (ER+) or PR-positive (PR+) tumors exhibit a stronger clinical response to hormone therapy than ER-negative (ER−) or PR-negative (PR−) breast cancer [7].